Endocrinology and most common biomarkers

Introduction to endocrinology

Endocrinology is the medical specialty focusing on hormones and the endocrine system which regulates most of the body’s physiological processes. Endocrinologists treat hormone imbalances and diseases of the endocrine glands. Common endocrine conditions like diabetes and thyroid disorders rely heavily on biomarker testing.

Biomarkers for diabetes screening and management

The three main biomarkers to check for diabetes or prediabetes are haemoglobin A1c (HbA1c), oral glucose tolerance tests, and fasting blood glucose. Home blood glucose monitoring allows diabetes patients to track levels. HbA1c, fructosamine, and emerging markers like 1,5-anhydroglucitol provide ongoing assessment of glucose control.

Microalbuminuria signals diabetic kidney damage. Cholesterol levels and inflammatory markers like hs-CRP predict cardiovascular risk, a diabetes complication. Biomarkers also track neuropathy and retinopathy progression.

Thyroid hormones and associated biomarkers

Thyroid-stimulating hormone (TSH) regulates production of T3 and T4 thyroid hormones. Elevated TSH indicates hypothyroidism while low TSH signals hyperthyroidism. T3 and T4 help determine thyroid function status and response to treatment.

The diagnosis of autoimmune thyroid disorders can be assisted by thyroid peroxidase and thyroglobulin antibodies. Calcitonin monitors for medullary thyroid cancer.

Biomarkers of adrenal function

Cortisol and DHEA-S levels test for Cushing’s syndrome or Addison’s disease of the adrenal cortex. Aldosterone and renin assess for adrenal gland hypo- or hyperactivity. Metanephrines screen for pheochromocytoma tumors.

Reproductive hormone biomarkers

FSH, LH, estrogen, and testosterone track ovarian/testicular function. Progesterone guides fertility treatment monitoring. hCG confirms pregnancy. Inhibin B evaluates fertility in males. AMH indicates ovarian reserve to assess female reproductive potential.

Neuroendocrine Tumor Markers

Prolactin screens for pituitary tumors. Chromogranin A marks neuroendocrine cancers. Serotonin, gastrin, and insulin-like growth factor 1 act as biomarkers to diagnose, stage, and monitor specific types of neuroendocrine tumors.

Osteoporosis biomarkers

Reduced bone mineral density and bone tissue degeneration are symptoms of osteoporosis. Key biomarkers assess fracture risk and monitor treatments. Bone turnover markers like PINP, CTX, and NTX indicate the rates of bone formation and resorption. Increased levels indicate faster bone loss. Vitamin D levels also estimate bone health status. Low vitamin D is associated with reduced BMD and increased fracture risk. DXA scans measure bone mineral density at the hip and spine to diagnose osteoporosis and quantify loss over time. FRAX algorithms integrate BMD and clinical risk factors to estimate 10-year fracture probability.

Biomarkers for adrenal insufficiency & hyperfunction

Aldosterone and plasma renin activity help identify primary adrenal insufficiency, like in Addison’s disease. Extremely low cortisol also diagnoses adrenal failure. Elevated cortisol, DHEA-S, and urine free cortisol screen for Cushing’s syndrome from excess cortisol. Dexamethasone suppression testing confirms hypercortisolism. Catecholamines like epinephrine, norepinephrine, and metanephrines diagnose pheochromocytoma, a catecholamine-secreting adrenal tumor.

Biomarkers to assess GH deficiency & excess

Growth hormone (GH) deficiency is diagnosed by low IGF-1 along with insufficient GH secretion on stimulation testing. Elevated IGF-1 indicates GH excess. GH testing directly is limited by pulsatile secretion. However, stimulation tests using arginine, clonidine, glucagon, or insulin induce GH release for assessment. IGF-binding proteins modify IGF-1 activity. IGFBP-3 often parallels IGF-1 levels while IGFBP-2 may increase in GH deficiency.

Future for endocrinology

Emerging technologies like metabolomics profiling and advanced MRI scanning may enable earlier diagnosis or detection of subtler endocrine abnormalities not findable through routine testing. Real-time, continuous hormone monitoring could improve management for diabetes and other conditions compared to periodic snapshots with current biomarkers. Nanotechnology and implantable sensors may make this possible.